Clinical Trial

A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.

Study acronym: Ipi4
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2023 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to understand how ipilimumab is being used, its safety profile, and the manner in which Adverse Reactions are managed in routine clinical practice. Another goal is to identify predictive biomarkers. The study is an observational study and not intended to test any hypothesis, but can be hypothesis generating.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2014-02-18; most recent amendment 2023-03-23.
Status change: Recruiting → Active, Not Recruiting 2015-04-09
Status change: Active, Not Recruiting → Recruiting 2014-11-21
Status change: Recruiting → Active, Not Recruiting 2014-10-30
Trial Details
NCT Number NCT02068196
Lead Sponsor Oslo University Hospital
Conditions Malignant Melanoma
Enrollment 150 participants
Start Date 2014-01
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-03-24